Ness Ziona, Israel – May 4, 2016 – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that BiondVax’s CEO, Dr. Ron Babecoff, will be attending the Joseph Gunnar Pioneers 2016 conference in New York City.

On Thursday, May 5, Dr. Babecoff will be presenting at 10:30am at Pioneers 2016, a conference presented by Joseph Gunner & Co, taking place at the New York Palace Hotel.

The BiondVax presentation that Dr. Babecoff will be using is downloadable from BiondVax’s website: http://www.biondvax.com/investor-presentation. Those wishing to meet one-on-one with Dr. Babecoff are invited to contact BiondVax.

About BiondVax Pharmaceuticals Ltd

BiondVax is a biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains. BiondVax’s proprietary technology utilizes a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. For more information, please visit www.biondvax.com.

For further information, please contact:

Company Contact
Joshua Phillipson
Business Development Manager
+972-8-930-2529 x5105
j.phillipson@biondvax.com
Investor Relations Contact
GK Investor Relations
Kenny Green, Partner
+1 646 201 9246
kenny@biondvax.com